FarmaMondo: Bringing Responsible Access Global
With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Switzerland AG
Zählerweg 6
CH 6300 Zug
Switzerland
Phone: +41 41 728 7444
Fax: +41 41 728 7440
www.biogenidec.ch
International Headquarters
Biogen Idec International GmbH
Landis & Gyr-Strasse 3
CH 6300 Zug
Switzerland
Phone: +41 41 39 21700
Fax: +41 41 39 21710
www.biogenidec-international.com
With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try…
Cristina Marti’s colorful and successful career has taken her across Asia from Spain, before settling in Switzerland with Indukern. In this interview, Marti explores themes of competition in Switzerland, the…
Karen Huebscher, CEO of Solvias, a Swiss-headquartered world leader in contract research, development and manufacturing, explains her decision to join the company after a distinguished career at Novartis, the evolution…
Marc Hasler, head of product and market development at Swiss Post, introduces the strategic significance of pharmaceuticals to the company, emerging trends in the logistics industry, and being a flagship…
Jan Denecker, marketing director healthcare at UPS Europe, introduces the logistics heavyweight’s broad portfolio of specialized services for the pharmaceutical industry, the significance of recent M&A activity, and what sets…
Dr. Teodoro Albarano, chief medical officer and vice CEO of Swiss skincare specialists Mavena, discusses why he decided to join the company after an illustrious career in Big Pharma, Mavena’s…
Laurent-Dominique Piveteau, CEO of Swiss medtech innovator Debiotech, discusses digital disruption, Swiss innovation, and future growth drivers. As well as being CEO of Debiotech, you also lecture courses at EPFL…
Alessandro di Napoli, CEO of Swiss family-owned pharmaceutical group, TRB Chemedica, discusses the company’s focus on the rheumatology, ophthalmology and neurology niches and the importance of ‘Swissness’ within its internationalization…
Dr. Raymond De Vré, senior VP and head of Business Operations and Strategy, Biologics at Dr. Reddy’s in Switzerland, discusses scaling up the Indian-headquartered company’s biosimilars business globally and the…
Kurt Reichen, VP Technical Operations at PaxVax, an American-headquartered fully integrated specialty vaccine company focused on infectious diseases, discusses the establishment of the company’s only site outside of the US…
Jürgen Pohle provides both a fascinating and open account of the latest movements of Neovii; a company that possesses the ability to make decisions at the speed of a startup…
Darren Kerr, CEO of Swiss medtech Stratpharma discusses, the company’s roots, its broad portfolio in dermatology, plastic surgery and scar management, as well as its growing international footprint. We…
See our Cookie Privacy Policy Here
